Preoperative chemotherapy is considered to play a role in early stage non small cell lung cancer (NSCLC) .The use of preoperative Cisplatin/Gemcitabine chemotherapy has proven feasible and without excessive morbidity or mortality in the Phase II setting. The aim of the present Phase III study is to determine whether 3 cycles of preoperative chemotherapy with Cisplatin/Gemcitabine improves progression free survival of NSCLC patients versus surgery alone. Postoperative chemotherapy will not be utilized in this Phase III trial.

Main inclusion Criteria:

• Must have pathologic documentation of non-small cell lung cancer, IB, II, IIIA.
• ECOG Performance Status of 0 - 1
• Bidimensionally measurable disease or evaluable disease
• Adequate organ function

Main exclusion Criteria:

• Have greater than Grade 1 neuropathy - motor/sensory
• Significant history of cardiac disease
• Pleural effusion

Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.